Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
COMPASS Pathways (Nasdaq: CMPS) announced the appointment of Danielle Schlosser, PhD, as Senior Vice-President of Clinical Innovation. Schlosser, who previously led behavioral health initiatives at Verily Life Sciences, will oversee the Therapy Research and Training team at COMPASS. The company, focused on innovative mental health solutions, is advancing its psilocybin therapy for treatment-resistant depression and is preparing for a phase III clinical trial. COMPASS has expanded its workforce to 100, enhancing its research and digital capabilities.
- Appointment of Danielle Schlosser, PhD, as Senior VP of Clinical Innovation.
- Strengthening of the Therapy Research and Training team.
- Expansion to 100 employees, enhancing R&D and digital capabilities.
- Progress toward phase III clinical trial for psilocybin therapy.
- None.
London, UK – 21 July 2021
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Danielle Schlosser PhD as Senior Vice-President, Clinical Innovation. Dr Schlosser will lead COMPASS’s Therapy Research and Training team, bringing her clinical experience in behavioural health and experience in digital health innovation.
Danielle Schlosser joins COMPASS from Verily Life Sciences, a sister company to Google, where she was Behavioural Health Lead, overseeing the launch of several products including digital measurement capabilities and clinical care initiatives. Danielle is a member of the World Economic Forum’s Global Future Council on Mental Health, and Chair of OneFifteen Health, a non-profit recovery ecosystem helping people who struggle with addiction and mental health disorders. She is also an Assistant Professor of Psychiatry at the University of California San Francisco.
Dr Schlosser said: “I am passionate about improving the mental health and wellbeing of people, at scale, and am inspired by COMPASS’s work and rapid progress in this area. I look forward to working with the team to bring therapies to patients who desperately need better options.”
Ekaterina Malievskaia MD, Chief Innovation Officer and Co-founder, COMPASS Pathways, said: “I am delighted to welcome Danielle to the team. Her clinical and digital innovation expertise will accelerate our work as we move towards a phase III clinical trial, and adds to the tremendous strength we now have in our digital and AI team. COMPASS continues to grow rapidly – we are now a team of 100 people, having expanded in a number of areas, including R&D, manufacturing, quality, and digital. This will enable us to work even more quickly, progressing our psilocybin therapy for treatment-resistant depression, expanding our portfolio into other areas of unmet need, and transforming mental health care. We all remain as committed as ever to bringing innovation to patients who aren’t helped by existing treatments.”
-Ends-
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com
Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, the efficacy of COMP360 psilocybin therapy as a treatment for depression, the expected timing for reporting data related to COMP360, COMPASS’s business strategy and goals, COMPASS’s ability to continue to advance its research, including COMP360, and COMPASS’s expectations regarding the benefits of its psilocybin therapy, including COMP360. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.
These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.
Enquiries
Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7423
FAQ
Who has been appointed as Senior VP of Clinical Innovation at COMPASS Pathways?
What is COMPASS Pathways focused on?
What is the current status of COMPASS's psilocybin therapy?
How many employees does COMPASS Pathways currently have?
What previous experience does Danielle Schlosser bring to COMPASS?
